But it points straight at something Sikiri's own lab published nearly thirty years ago
Tirzepatide works by targeting two important receptors in the body: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)
Unguided self-medication carries many potential risks such as incorrect self-diagnosis, dangerous drug interactions, incorrect manner of administration, severe adverse reactions, and masking of severe disease
Clinically, BBB derangements in this spectrum of conditions lead to a higher risk of remote cerebral hemorrhage and HT of the infarcted area after thrombolysis in patients with cSVD (178, 236238)
Proudman, S
It inhibits the activation of the transcription factor NF-B, reducing the production of pro-inflammatory cytokines (IL-1, TNF-, IL-6) and inflammatory mediators (PGE2, NO)